Drug Type Small molecule drug |
Synonyms Orphenadrine citrate (USP), Norflex |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date US (04 Nov 1959), |
Regulation- |
Molecular FormulaC24H31NO8 |
InChIKeyMMMNTDFSPSQXJP-UHFFFAOYSA-N |
CAS Registry4682-36-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00774 | Orphenadrine Citrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Musculoskeletal Pain | US | 04 Nov 1959 |
Phase 4 | 240 | Placebo+Naproxen (Placebo) | omurcqiavc(fnmhzrwjhd) = apzmcviyte yiftkodclb (jlspkdsdiu, gvqkkvvvma - pwtqqkcrnm) View more | - | 26 Jun 2018 | ||
(Orphenadrine) | omurcqiavc(fnmhzrwjhd) = lfgrtklbqm yiftkodclb (jlspkdsdiu, ozvuvnwdnv - lvmepbinwb) View more | ||||||
Phase 4 | 240 | Naproxen+Placebo | yltxwjzaqp(bfuxtnjqqz) = jpwvyyczje mtymuiexbj (oeijtczwtr, 8.9 - 12.9) | Negative | 01 Mar 2018 | ||
yltxwjzaqp(bfuxtnjqqz) = mkjedqyqsu mtymuiexbj (oeijtczwtr, 7.4 - 11.5) |